Related Experiment Videos
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome
David Kavanagh1, Elizabeth J Kemp, Elizabeth Mayland
1Institute of Human Genetics, University of Newcastle upon Tyne, Tyne and Wear NE1 3BZ, UK.
Journal of the American Society of Nephrology : JASN
|May 27, 2005
Summary
Mutations in complement factor I (IF) were identified in two patients with atypical hemolytic uremic syndrome (HUS). This suggests IF mutations contribute to complement dysregulation in HUS, a serious kidney condition.
Area of Science:
- Immunology
- Genetics
- Nephrology
Background:
- Atypical hemolytic uremic syndrome (HUS) is linked to mutations in complement regulators factor H (CFH) and membrane co-factor protein (MCP).
- Complement factor I (IF) regulates complement pathways by cleaving C3b and C4b, preventing excessive activation.
Purpose of the Study:
- To investigate the role of complement factor I (IF) mutations in patients diagnosed with atypical hemolytic uremic syndrome (HUS).
Main Methods:
- Screened a cohort of 76 patients with HUS for mutations in the gene encoding complement factor I (IF).
- Analyzed identified mutations for their impact on serum IF levels and correlated findings with clinical presentation, including recurrence post-transplantation.
Main Results:
- Mutations in IF were found in two out of 76 HUS patients, both exhibiting reduced serum IF levels.
- One patient had a c.463 G>A mutation (W127X), and the other had a del 922C deletion in exon 7.
- Both patients with IF mutations experienced recurrent HUS after transplantation, similar to CFH mutation carriers.
Conclusions:
- These findings provide additional evidence that atypical HUS is a disorder of complement dysregulation.
- Mutations in IF are implicated in the pathogenesis of atypical HUS.
- The recurrence pattern of IF-associated HUS post-transplantation mirrors that of CFH mutations.